secwatch.observer — SEC 8-K summary
======================================

Issuer:     Drugs Made In America Acquisition Corp. (DMAA)
CIK:        0002028614
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001213900-26-035502
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 8.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DMAA SPAC enters $100K convertible bridge as first step of $500K financing; identifies AI/cybersecurity target
--------------------------------------------------------------------------------

- BV Advisory Partners provides $100K convertible note (up to $500K total) for compliance and transaction expenses.
- Note converts at 35% discount to post-merger market value, matures in 6 months, no interest, no trust account claim.
- Investor introduced potential target: enterprise AI/ML, quantum analytics, cybersecurity platform (Power Analytics Global).
- Company to pursue replacement sponsor and provide investor ≥40% sponsor-level economics; no definitive agreement yet.
- Proceeds used for audit, Nasdaq, legal, proxy, extension fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/ea0283803-8k_drugs.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-035502

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer